Log in

NASDAQ:PRTA - Prothena Stock Price, Forecast & News

-0.09 (-0.75 %)
(As of 02/24/2020 03:11 AM ET)
Today's Range
Now: $11.88
50-Day Range
MA: $13.64
52-Week Range
Now: $11.88
Volume168,019 shs
Average Volume133,741 shs
Market Capitalization$473.81 million
P/E RatioN/A
Dividend YieldN/A
Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:PRTA



Sales & Book Value

Annual Sales$810,000.00
Book Value$8.10 per share


Net Income$-77,680,000.00
Net Margins-9,542.63%


Market Cap$473.81 million
Next Earnings Date5/5/2020 (Estimated)

Receive PRTA News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTA and its competitors with MarketBeat's FREE daily newsletter.

Prothena (NASDAQ:PRTA) Frequently Asked Questions

What is Prothena's stock symbol?

Prothena trades on the NASDAQ under the ticker symbol "PRTA."

How were Prothena's earnings last quarter?

Prothena Co. PLC (NASDAQ:PRTA) issued its quarterly earnings data on Wednesday, February, 12th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.11. The biotechnology company earned $0.26 million during the quarter, compared to the consensus estimate of $0.20 million. Prothena had a negative net margin of 9,542.63% and a negative return on equity of 25.77%. View Prothena's Earnings History.

When is Prothena's next earnings date?

Prothena is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for Prothena.

What price target have analysts set for PRTA?

4 analysts have issued 12 month price targets for Prothena's stock. Their forecasts range from $9.00 to $19.00. On average, they anticipate Prothena's stock price to reach $13.94 in the next twelve months. This suggests a possible upside of 17.4% from the stock's current price. View Analyst Price Targets for Prothena.

What is the consensus analysts' recommendation for Prothena?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Prothena in the last year. There are currently 1 sell rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Prothena.

Has Prothena been receiving favorable news coverage?

Press coverage about PRTA stock has been trending positive on Monday, according to InfoTrie. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Prothena earned a daily sentiment score of 2.6 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Prothena.

Who are some of Prothena's key competitors?

What other stocks do shareholders of Prothena own?

Who are Prothena's key executives?

Prothena's management team includes the folowing people:
  • Mr. Gene G. Kinney, Pres, CEO & Director (Age 50)
  • Mr. Tran B. Nguyen, CFO & COO (Age 45)
  • Mr. Arthur W. Homan, Chief Legal Officer & Company Sec. (Age 60)
  • Ms. Karin L. Walker, Chief Accounting Officer & Controller (Age 56)
  • Dr. Wagner M. Zago, Chief Scientific Officer (Age 46)

Who are Prothena's major shareholders?

Prothena's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (8.34%), State Street Corp (2.60%), Palo Alto Investors LP (2.49%), Geode Capital Management LLC (1.43%), Goldman Sachs Group Inc. (1.18%) and Pinnacle Associates Ltd. (1.00%). View Institutional Ownership Trends for Prothena.

Which major investors are selling Prothena stock?

PRTA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Oxford Asset Management LLP, Platinum Investment Management Ltd., FMR LLC, Rafferty Asset Management LLC, UBS Group AG, Citigroup Inc. and Man Group plc. View Insider Buying and Selling for Prothena.

Which major investors are buying Prothena stock?

PRTA stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Pinnacle Associates Ltd., Goldman Sachs Group Inc., Acadian Asset Management LLC, Geode Capital Management LLC, Ikarian Capital LLC, Russell Investments Group Ltd. and Driehaus Capital Management LLC. View Insider Buying and Selling for Prothena.

How do I buy shares of Prothena?

Shares of PRTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Prothena's stock price today?

One share of PRTA stock can currently be purchased for approximately $11.88.

How big of a company is Prothena?

Prothena has a market capitalization of $473.81 million and generates $810,000.00 in revenue each year. The biotechnology company earns $-77,680,000.00 in net income (profit) each year or ($1.95) on an earnings per share basis. Prothena employs 59 workers across the globe.View Additional Information About Prothena.

What is Prothena's official website?

The official website for Prothena is http://www.prothena.com/.

How can I contact Prothena?

Prothena's mailing address is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN L2, D02 T804. The biotechnology company can be reached via phone at 011-353-1236-2500 or via email at [email protected]

MarketBeat Community Rating for Prothena (NASDAQ PRTA)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  517 (Vote Outperform)
Underperform Votes:  401 (Vote Underperform)
Total Votes:  918
MarketBeat's community ratings are surveys of what our community members think about Prothena and other stocks. Vote "Outperform" if you believe PRTA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel